Barclays’s Kindred Biosciences, Inc. KIN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-174,042
| Closed | -$1.6M | – | 5120 |
|
|
2021
Q2 | $1.6M | Buy |
174,042
+142,896
| +459% | +$831K | ﹤0.01% | 2351 |
|
|
2021
Q1 | $155K | Buy |
31,146
+19,119
| +159% | +$92.3K | ﹤0.01% | 3817 |
|
|
2020
Q4 | $52K | Sell |
12,027
-5,182
| -30% | -$21.1K | ﹤0.01% | 4388 |
|
|
2020
Q3 | $74K | Sell |
17,209
-3,217
| -16% | -$13.4K | ﹤0.01% | 4406 |
|
|
2020
Q2 | $93K | Buy |
20,426
+8,145
| +66% | +$36.4K | ﹤0.01% | 4576 |
|
|
2020
Q1 | $49K | Sell |
12,281
-24,769
| -67% | -$210K | ﹤0.01% | 5250 |
|
|
2019
Q4 | $314K | Buy |
37,050
+18,538
| +100% | +$145K | ﹤0.01% | 4688 |
|
|
2019
Q3 | $127K | Sell |
18,512
-5,369
| -22% | -$39.4K | ﹤0.01% | 5309 |
|
|
2019
Q2 | $199K | Buy |
23,881
+11,426
| +92% | +$98.6K | ﹤0.01% | 5117 |
|
|
2019
Q1 | $114K | Buy |
12,455
+12,057
| +3,029% | +$122K | ﹤0.01% | 5263 |
|
|
2018
Q4 | $4K | Sell |
398
-11,982
| -97% | -$151K | ﹤0.01% | 6567 |
|
|
2018
Q3 | $173K | Buy |
12,380
+8,982
| +264% | +$122K | ﹤0.01% | 5125 |
|
|
2018
Q2 | $36K | Sell |
3,398
-1,879
| -36% | -$18.3K | ﹤0.01% | 5858 |
|
|
2018
Q1 | $45K | Buy |
5,277
+1,287
| +32% | +$11.3K | ﹤0.01% | 5979 |
|
|
2017
Q4 | $38K | Buy |
3,990
+3,406
| +583% | +$26.6K | ﹤0.01% | 5921 |
|
|
2017
Q3 | $5K | Sell |
584
-2,228
| -79% | -$16.7K | ﹤0.01% | 6443 |
|
|
2017
Q2 | $24K | Sell |
2,812
-11,808
| -81% | -$84.7K | ﹤0.01% | 5714 |
|
|
2017
Q1 | $103K | Buy |
+14,620
| New | +$91.6K | ﹤0.01% | 4862 |
|
|
2015
Q2 | – | Sell |
-316
| Closed | -$2K | – | 7290 |
|
|
2015
Q1 | $2K | Sell |
316
-536
| -63% | -$3.69K | ﹤0.01% | 6906 |
|
|
2014
Q4 | $6K | Sell |
852
-9,814
| -92% | -$83.2K | ﹤0.01% | 6944 |
|
|
2014
Q3 | $96K | Buy |
10,666
+10,258
| +2,514% | +$139K | ﹤0.01% | 5367 |
|
|
2014
Q2 | $7K | Buy |
408
+173
| +74% | +$2.94K | ﹤0.01% | 7019 |
|
|
2014
Q1 | $4K | Buy |
+235
| New | +$4.48K | ﹤0.01% | 7293 |
|
Other funds holding KIN
Barclays's KIN Position: Q3 2021 in Review
Barclays sold out of Kindred Biosciences, Inc. (KIN) in Q3 2021, closing a stake of 174,042 shares — an estimated $1.6M sold.
Barclays first reported a position in KIN in Q1 2014 and held it in 23 quarters. The position peaked at $1.6M in Q2 2021. 1 fund tracked by Wall St. Rank holds KIN as of Q3 2021.
- Barclays reported no remaining Kindred Biosciences, Inc. position as of Q3 2021 after selling out during the quarter.
- Barclays sold 174,042 Kindred Biosciences, Inc. shares in Q3 2021, an estimated $1.6M.
- Barclays first reported a position in Kindred Biosciences, Inc. in Q1 2014 and held it in 23 quarters.
- Barclays's Kindred Biosciences, Inc. position peaked at $1.6M in Q2 2021.
- 1 fund tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q3 2021.
Based on Barclays's 13F filing for Q3 2021, filed 9 Nov 2021.